TY - JOUR
T1 - Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases
AU - Horimoto, Y.
AU - Arakawa, A.
AU - Harada-Shoji, N.
AU - Sonoue, H.
AU - Yoshida, Y.
AU - Himuro, T.
AU - Igari, F.
AU - Tokuda, E.
AU - Mamat, O.
AU - Tanabe, M.
AU - Hino, O.
AU - Saito, M.
N1 - Publisher Copyright:
© 2015 Cancer Research UK. All rights reserved.
PY - 2015/1/20
Y1 - 2015/1/20
N2 - Background: FOXA1 expression is a good prognostic marker for endocrine therapy in hormone-positive breast cancer. We retrospectively examined breast cancer patients with luminal human epidermal growth factor receptor 2 (HER2)-negative tumours, as defined by immunohistochemistry, who received neo-adjuvant chemotherapy (NAC) and investigated the relationship between treatment effects and FOXA1 expression. Methods: Biopsy specimens from 103 luminal HER2-negative tumours were immunohistochemically examined. FOXA1 effects on chemo-sensitivity were also investigated employing in vitro experiments. Results: FOXA1 and Ki67 expressions independently predicted a pathological complete response (pCR). Knockdown of FOXA1 by siRNA boosted the chemo-effect in oestrogen receptor-positive cells. The Cox hazards model revealed a pCR to be the strongest factor predicting a good patient outcome. Conclusions: Our present study showed low FOXA1 expression to be associated with a good response to NAC in luminal HER2-negative breast cancer. Improved outcomes of these patients suggest that NAC should be recommended to patients with low FOXA1 tumours.
AB - Background: FOXA1 expression is a good prognostic marker for endocrine therapy in hormone-positive breast cancer. We retrospectively examined breast cancer patients with luminal human epidermal growth factor receptor 2 (HER2)-negative tumours, as defined by immunohistochemistry, who received neo-adjuvant chemotherapy (NAC) and investigated the relationship between treatment effects and FOXA1 expression. Methods: Biopsy specimens from 103 luminal HER2-negative tumours were immunohistochemically examined. FOXA1 effects on chemo-sensitivity were also investigated employing in vitro experiments. Results: FOXA1 and Ki67 expressions independently predicted a pathological complete response (pCR). Knockdown of FOXA1 by siRNA boosted the chemo-effect in oestrogen receptor-positive cells. The Cox hazards model revealed a pCR to be the strongest factor predicting a good patient outcome. Conclusions: Our present study showed low FOXA1 expression to be associated with a good response to NAC in luminal HER2-negative breast cancer. Improved outcomes of these patients suggest that NAC should be recommended to patients with low FOXA1 tumours.
KW - FOXA1
KW - Luminal breast cancer
KW - Neo-adjuvant chemotherapy
KW - Pathological complete response
UR - http://www.scopus.com/inward/record.url?scp=84922337369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922337369&partnerID=8YFLogxK
U2 - 10.1038/bjc.2014.595
DO - 10.1038/bjc.2014.595
M3 - Article
C2 - 25422910
AN - SCOPUS:84922337369
VL - 112
SP - 345
EP - 351
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 2
ER -